Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

Rodenburg, Gerwin D.; de Greeff, Sabine C.; Jansen, Angelique G.C.S.; de Melker, Hester E.; Schouls, Leo M.; Hak, Eelko; Spanjaard, Lodewijk; Sanders, Elisabeth A.M.; van der Ende, Arie

Back to Previous Page

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

Published Date:

May 2010

Source:

Emerg Infect Dis. 16(5):816-823.

[PDF-271.87 KB]

Details:

Alternative Title:

Emerg Infect Dis

Personal Author:

Rodenburg, Gerwin D. ; de Greeff, Sabine C. ; Jansen, Angelique G.C.S. ; de Melker, Hester E. ; Schouls, Leo M. ; ... More ▼

Description:

In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program for infants born after April 1, 2006. To assess the vaccine's effectiveness, we compared disease incidence before and after vaccine implementation (June 2004-June 2006 and June 2006-June 2008, respectively). We serotyped 2,552 invasive pneumococcal isolates from throughout the Netherlands, covering 25% of the country's population. Clinical characteristics were extracted from hospital records. After June 2006, vaccine-serotype invasive pneumococcal disease (IPD) decreased 90% (95% confidence interval [CI] 68%-97%) in children age eligible for PCV-7; simultaneously, however, non-vaccine-serotype IPD increased by 71% (not significant), resulting in a 44% total net IPD reduction (95% CI 7%-66%). IPD rates did not change for other age groups. In the Netherlands, PCV-7 offered high protection against vaccine-serotype IPD in vaccinated children, but increases of non-vaccine-serotype IPD reduced net vaccine benefits.

Subject:

[+]

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Main Document Checksum:

[+]

File Type:

Supporting Files:

	09-1223-F5.gif	image/gif
	09-1223-F5.jpg	image/jpeg
	09-1223_finalR.nxml	text/plain
	license.txt	text/plain
	09-1223-F1.gif	image/gif
	09-1223-F1.jpg	image/jpeg
	09-1223-F2.gif	image/gif
	09-1223-F2.jpg	image/jpeg
	09-1223-F3.gif	image/gif
	09-1223-F3.jpg	image/jpeg
	09-1223-F4.gif	image/gif
	09-1223-F4.jpg	image/jpeg

No Related Documents.

Carriage of Streptococcus pneumoniae 3 Years after Start of Vaccination Program, the Netherlands

[PDF - 260.92 KB]

Personal Author:

Spijkerman, Judith ; van Gils, Elske J.M. ; ...

Published Date:

Apr 2011

Source:

Emerg Infect Dis. 17(4):584-591.

Description:

To evaluate the effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7) program, we conducted a cross-sectional observational study on nas...

File Type:

[PDF - 260.92 KB]

File Type:

[PDF - 260.92 KB]
Pediatric Pneumococcal Serotypes in 4 European Countries

[PDF - 764.84 KB]

Personal Author:

Hanquet, Germaine ; Kissling, Esther ; ...

Published Date:

Sep 2010

Source:

Emerg Infect Dis. 16(9):1428-1439.

Description:

After heptavalent pneumococcal conjugate vaccine (PCV7) was marketed in France, Spain, Belgium, and England and Wales (United Kingdom), invasive disea...

File Type:

[PDF - 764.84 KB]

File Type:

[PDF - 764.84 KB]
Invasive Bacterial Diseases in Northern Canada

[PDF - 161.03 KB]

Personal Author:

Degani, Naushaba ; Navarro, Christine ; ...

Corporate Authors:

Canadian International Circumpolar Surveillance Working Group

Published Date:

Jan 2008

Source:

Emerg Infect Dis. 14(1):34-40.

Description:

International Circumpolar Surveillance (ICS) is a population-based invasive bacterial disease surveillance network. Participating Canadian regions inc...

File Type:

[PDF - 161.03 KB]

File Type:

[PDF - 161.03 KB]
Emergence of Streptococcus pneumoniae Serotype 12F after Sequential Introduction of 7- and 13-Valent Vaccines, Israel

[PDF - 2.43 MB]

Personal Author:

Rokney, Assaf ; Ben-Shimol, Shalom ; ...

Published Date:

Mar 2018

Source:

Emerg Infect Dis. 24(3):453-461.

Description:

Israel implemented use of 7- and 13-valent pneumococcal vaccine in 2009 and 2010, respectively. We describe results of prospective, population-based, ...

File Type:

[PDF - 2.43 MB]

File Type:

[PDF - 2.43 MB]
CDC recommends suspension of the routine use of the third and fourth doses of pneumococcal conjugate vaccine (Prevnar®)

[PDF - 750.63 KB]

Corporate Authors:

Centers for Disease Control and Prevention (U.S.)

Published Date:

3/2/04

Series:

HAN ; 187

Description:

Tuesday, March 02, 2004, 16:26 EST (04:26 PM EST)CDCHAN-00187-2004-03-02-ADV-NAll health-care providers should temporarily suspend routine use of both...

File Type:

[PDF - 750.63 KB]

File Type:

[PDF - 750.63 KB]

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

You May Also Like:

Have Questions?

CDC INFORMATION

CONNECT WITH CDC